Decision for fibrinolysis or primary PCI in the prehospital phase

Size: px
Start display at page:

Download "Decision for fibrinolysis or primary PCI in the prehospital phase"

Transcription

1 Decision for fibrinolysis or primary PCI in the prehospital phase Nicolas Danchin, Hôpital Européen Georges Pompidou, Paris, France

2 Disclosures Research grants: Astrazeneca, Eli-Lilly, GSK, Merck, Novartis, Pfizer, Sanofi-aventis, Servier, The MedCo Fees for giving lectures and/or consulting: Astrazeneca, BMS, Boehringer-Ingelheim, GSK, Lilly, MSD-Schering, Novartis, Novo-Nordisk, Pfizer, sanofi-aventis, Servier, The MedCo

3 Background: fibrinolysis vs ppci in STEMI Randomised controlled trials have shown the superiority of primary PCI over fibrinolysis. 16 Lysis PCI Death Re-MI Stroke Death, MI, stroke Keeley et al. Lancet 2003

4 Overall, there is an about 40% reduction in ischemic events with ppci, compared with lytic treatment But

5 Real life may be different from RCTs: times to PCI are often very long Old trials all compared primary PCI with stand-alone fibrinolytic treatment: DANAMI-2: clear benefits of PPCI even in transfer patients 10% 8% Death P= % 6.6% DANAMI-2: Results 8% 6% Recurrent MI P< % 8% 6% Stroke P=0.15 6% Rescue PCI: 1.9% 4% 2% 4% 2% 1.6% 4% 2% 2.0% 1.1% Any PCI: 16.4% 0% 0% Lytic Primary PCI 0% Lytic Primary PCI Lytic Primary PCI N Engl J Med 2003; 349:

6 Management of STEMI in the real world: time delays

7 % of Patients Time Delays for PPCI in Non-Transfer Patients NCDR , ,6 23, ,8 3,2 4,2 2 1,1 1,7 < Rathore et al. BMJ 2009 Total Door-to-Balloon Time (minutes)

8 % of Patients Time Delays in Transfer Patients for Primary PCI <1 1 to <2 2 to <3 3 to <4 4 to <5 5 to <6 6 to <7 >=7 Total Door-to-Balloon Time (Hours) Nallamothu et al. Circulation 2005.

9 GRACE: Trends in time delays Door to reperfusion PCI only 75 (45-125) Fibrinolytic therapy only 35 (21-62) (45-119) 34 (17-62) Eagle et al. EHJ 2008

10 Fibrinolysis should not be used as a stand-alone procedure

11 REACT trial: rescue PCI 427 patients <50% ST resolution 90 min after lysis R'dom: rescue PCI repeat lysis conservative NEJM 2005; 353:

12 Ischaemic event rate (%) Routine early invasive approach after lysis Time from fibrinolysis to routine early PCI (hr) Verheugt FWA. N Engl J Med 2009;360:

13 266 patients randomised NORwegian study on District treatment of ST-Elevation Myocardial Infarction NORDISTEMI 30-day outcome Death, MI, or stroke Bohmer et al., JACC 2010

14 Overall, comparisons of a pharmaco-invasive strategy including both rescue PCI and routine, semi-urgent PCI with stand-alone fibrinolysis show a 50% reduction in the risk of combined CV ischemic events

15 Fibrinolysis vs ppci: real-world data

16 FAST-MI 2005 and 2010: in-hospital mortality ,7 4,7 1,7 4,1 3,0 3,0 6,1 0 Primary PCI Lysis PH lysis 0,0 IH lysis Lysis ppci Initial TIMI flow 2 or 3 50% 29% Final LVEF 53.1 ± ± 12.6

17 Three French surveys, 5 years apart USIK month death if admission 3 hrs: 7.7% vs 12.0% PHT PPCI IHT No reperf USIC yr death in pts calling 120 min 5.3 vs 9.4 vs 10.7% FAST-MI 2005 Adjusted HR 0.49 [ ] Circulation 1999; Circulation 2004; Circulation 2008

18 Pros and cons of fibrinolysis in the specific context of OHCA

19 Pros of fibrinolysis Fibrinolysis is more efficacious when the patients are seen very early Aborted MI with PH-fibrinolysis Boersma, 1996; Lamfers PHT 4 IHT

20 Cons of fibrinolysis Intrinsic bleeding risk: specific risk in OHCA? Cannot confirm diagnosis of STEMI: Initial series of Spaulding et al. (NEJM 1997) In a recent series of 158 OHCA with ST elevation after resuscitation, 97% had CAD; in 54 pts with ST-T changes without ST elevation, 41% had no CAD (Radsel et al, Am J Cardiol 2011)

21 Cons of fibrinolysis: the TROICA trial Specific context of ongoing resuscitation and failed defibrillation attempts. About 70% presumed AMIs No benefit of fibrinolytic treatment (tenecteplase mg, weight-adjusted): Similar death rate and cerebral function recovery 30-day survival Increased risk of intracranial bleeding (2.7 v. 0.4) Böttiger et al. NEJM 2008

22 Primary PCI in OHCA: the PROCAT registry 435 patients with CAG after OHCA CAD present in 96% with ST-elevation and 58% without ST-elevation PCI associated with improved survival (OR= 2.06) Dumas et al. Circ CV Interv 2010

23 Summary After OHCA, fibrinolysis is a potentially valid option if: ST-elevation is present on ECG Expected time to primary PCI is too long Followed by semi-urgent coronary angiography In the absence of ST-segment elevation, coronary angiography is warranted if there is no other obvious cause for cardiac arrest

SHOULD A REGIONAL STEMI CENTRE ONLY OFFER PRIMARY PCI?

SHOULD A REGIONAL STEMI CENTRE ONLY OFFER PRIMARY PCI? SHOULD A REGIONAL STEMI CENTRE ONLY OFFER PRIMARY PCI? Kurt Huber, MD 3 Department of Internal Medicine, Cardiology and Intensive Care Medicine, Wilhelminenhospital, Vienna, Austria Disclosures DISCLOSURE

More information

Current Advances and Best Practices in Acute STEMI Management A pharmacoinvasive approach

Current Advances and Best Practices in Acute STEMI Management A pharmacoinvasive approach Current Advances and Best Practices in Acute STEMI Management A pharmacoinvasive approach Frans Van de Werf, MD, PhD University Hospitals, Leuven, Belgium Frans Van de Werf: Disclosures Research grants

More information

STREAM - ONE YEAR MORTALITY STRATEGIC REPERFUSION EARLY AFTER MYOCARDIAL INFARCTION. STREAM 1Y AHA 2013 P Sinnaeve

STREAM - ONE YEAR MORTALITY STRATEGIC REPERFUSION EARLY AFTER MYOCARDIAL INFARCTION. STREAM 1Y AHA 2013 P Sinnaeve STREAM - ONE YEAR MORTALITY STRATEGIC REPERFUSION EARLY AFTER MYOCARDIAL INFARCTION PCI Hospital Ambulance/ER STREAM design STEMI

More information

The Strategic Reperfusion Early After STEMI study Implications for clinical practice

The Strategic Reperfusion Early After STEMI study Implications for clinical practice The Strategic Reperfusion Early After STEMI study Implications for clinical practice Robert C. Welsh, MD, FRCPC Associate Professor of Medicine Director, Adult Cardiac Catheterization and Interventional

More information

New Insights on Reperfusion Choices Implications of STREAM. Paul W Armstrong MD

New Insights on Reperfusion Choices Implications of STREAM. Paul W Armstrong MD New Insights on Reperfusion Choices Implications of STREAM ESC STEMI Satellite Symposium August 31 2014 Aligning Optimal Care to Time Place and Person Paul W Armstrong MD Disclosure Statement Paul W. Armstrong

More information

The Window for Fibrinolysis. Frans Van de Werf, MD, PhD Leuven, Belgium

The Window for Fibrinolysis. Frans Van de Werf, MD, PhD Leuven, Belgium The Window for Fibrinolysis Frans Van de Werf, MD, PhD Leuven, Belgium ESC STEMI Guidelines : December 2008 Reperfusion Therapy: Fibrinolytic Therapy Recommendations Class LOE In the absence of contraindications

More information

Out-of-hospital Cardiac Arrest. Franz R. Eberli MD, FESC, FAHA Cardiology Triemli Hospital Zurich, Switzerland

Out-of-hospital Cardiac Arrest. Franz R. Eberli MD, FESC, FAHA Cardiology Triemli Hospital Zurich, Switzerland Out-of-hospital Cardiac Arrest Franz R. Eberli MD, FESC, FAHA Cardiology Triemli Hospital Zurich, Switzerland Conflict of Interest I have no conflict of interest to disclose regarding this presentation.

More information

Clinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective

Clinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Clinical Seminar Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical

More information

STEMI Care 2014 at the Crossroads: Taking the right road

STEMI Care 2014 at the Crossroads: Taking the right road STEMI Care 2014 at the Crossroads: Taking the right road Robert C. Welsh, MD, FRCPC, FESC, FAHA, FACC Professor of Medicine Vice President, The Canadian Association of Interventional Cardiology Director,

More information

Coronary Angiography after Cardiac Arrest without ST-Segment Elevation: the COACT trial

Coronary Angiography after Cardiac Arrest without ST-Segment Elevation: the COACT trial Coronary Angiography after Cardiac Arrest without ST-Segment Elevation: the On behalf of the COACT investigators Jorrit Lemkes, MD, Interventional cardiologist Amsterdam UMC, Vrije Universiteit Amsterdam,

More information

Critics of Thrombolytics: Is Pre-Hospital Clot-busting Actually a Bad Thing? David Persse, MD Houston Fire Department EMS

Critics of Thrombolytics: Is Pre-Hospital Clot-busting Actually a Bad Thing? David Persse, MD Houston Fire Department EMS Critics of Thrombolytics: Is Pre-Hospital Clot-busting Actually a Bad Thing? David Persse, MD Houston Fire Department EMS STEMI Stuff New or Recurrent MI s in U.S.: 865,000 Acute STEMI s: 500,000 Sooner

More information

DECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.

DECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck. DECLARATION OF CONFLICT OF INTEREST Lecture fees: AstraZeneca, Ely Lilly, Merck. Risk of stopping dual therapy. S D Kristensen, FESC Aarhus Denmark Acute coronary syndrome: coronary thrombus Platelets

More information

Antithrombotic treatment in ACS: what do the guidelines say? Nicolas Danchin, HEGP, Paris France

Antithrombotic treatment in ACS: what do the guidelines say? Nicolas Danchin, HEGP, Paris France Antithrombotic treatment in ACS: what do the guidelines say? Nicolas Danchin, HEGP, Paris France Disclosures Research grants: Astra-Zeneca, Merck, Novartis, Pfizer, sanofi-aventis, Servier, The MedCo Fees

More information

The Need for Rescue PCI after Failed Fibrinolysis: Who, When and Why.

The Need for Rescue PCI after Failed Fibrinolysis: Who, When and Why. Implementing the pharmacoinvasive strategy in STEMI The Need for Rescue PCI after Failed Fibrinolysis: Who, When and Why. 7:20-7:40 Robert C. Welsh, MD, FRCPC, FESC, FAHA, FACC Professor of Medicine Director,

More information

Patient Transfer. Mark de Belder The James Cook University Hospital Middlesbrough

Patient Transfer. Mark de Belder The James Cook University Hospital Middlesbrough Patient Transfer Mark de Belder The James Cook University Hospital Middlesbrough Current Management Strategies for ACS ACS No ST Elevation ST ST Elevation Elevation Early Invasive Early Conservative Fibrinolysis

More information

Overcoming the Risk-Treatment Paradox in Non-STE ACS: It s Time! Christopher Granger, MD

Overcoming the Risk-Treatment Paradox in Non-STE ACS: It s Time! Christopher Granger, MD Overcoming the Risk-Treatment Paradox in Non-STE ACS: It s Time! Christopher Granger, MD Disclosures Research contracts: AstraZeneca, Bayer, Novartis, GSK, Sanofi-Aventis, BMS, Pfizer, The Medicines Company,

More information

Pharmaco-Invasive Approach for STEMI

Pharmaco-Invasive Approach for STEMI Pharmaco-Invasive Approach for STEMI Michael C. Kontos, MD Medical Director, Coronary Intensive Care Unit Director, Chest Pain Evaluation Center Associate Professor Departments of Internal Medicine (Cardiology),

More information

Recommendations for criteria for STEMI systems of care: A focus on pharmacoinvasive strategies

Recommendations for criteria for STEMI systems of care: A focus on pharmacoinvasive strategies Recommendations for criteria for STEMI systems of care: A focus on pharmacoinvasive strategies Mohammad Zubaid, MB, ChB, FRCPC, FACC Professor of Medicine, Kuwait University Chairman, Faculty of Cardiology,

More information

Hot Topics in Cardiac Arrest. Should the patient go To the Cath Lab?

Hot Topics in Cardiac Arrest. Should the patient go To the Cath Lab? Hot Topics in Cardiac Arrest Should the patient go To the Cath Lab? Tim Russert 1950-2008 Host of NBC s Meet the Press Sudden Cardiac Arrest : Autopsy showed plaque rupture in his LAD ( per LA Times,

More information

ACC Rockies New Role For An Old Friend: Contemporary Insights From The ECG

ACC Rockies New Role For An Old Friend: Contemporary Insights From The ECG ACC Rockies 2012 New Role For An Old Friend: Contemporary Insights From The ECG Paul W. Armstrong, MD Monday March 12 2012 2012 Disclosure Statement Paul W. Armstrong MD Details available @ http://www.vigour.ualberta.ca

More information

Conflits d intérêt Astra-Zeneca, BMS, MSD, Novartis, Pfizer, Daiichi-Sankyo, Servier, CRAM, AFSSAPS, ARH Région de Bourgogne Clos Vougeot

Conflits d intérêt Astra-Zeneca, BMS, MSD, Novartis, Pfizer, Daiichi-Sankyo, Servier, CRAM, AFSSAPS, ARH Région de Bourgogne Clos Vougeot Conflits d intérêt Astra-Zeneca, BMS, MSD, Novartis, Pfizer, Daiichi-Sankyo, Servier, CRAM, AFSSAPS, ARH Région de Bourgogne Clos Vougeot Agrément FMC N 100 437 Popul. millions Area km2 Density inha/km2

More information

Primary Percutaneous Coronary Intervention

Primary Percutaneous Coronary Intervention The big 5 in PCI Primary Percutaneous Coronary Intervention W. Wijns (Aalst, BE) Disclosures Consulting Fees: on my behalf go to the Cardiovascular Research Center Aalst Contracted Research between the

More information

DECLARATION OF CONFLICT OF INTEREST. Research grants: Sanofi-Aventis

DECLARATION OF CONFLICT OF INTEREST. Research grants: Sanofi-Aventis DECLARATION OF CONFLICT OF INTEREST Research grants: Sanofi-Aventis Invasive management after cardiac arrest Nikolaos I Nikolaou FESC, FERC Athens, Greece Survival (%) Survival from Out of Hospital Cardiac

More information

DES in primary PCI for STEMI: contra

DES in primary PCI for STEMI: contra DES in primary PCI for STEMI: contra Philippe Gabriel Steg Department of Cardiology Hôpital Bichat Claude Bernard, AP-HP Université Paris VII Denis Diderot INSERM U-698 Paris, France Ph. Gabriel Steg -

More information

Regional STEMI Transfer Systems: the Mayo and NC RACE Experiences

Regional STEMI Transfer Systems: the Mayo and NC RACE Experiences Regional STEMI Transfer Systems: the Mayo and NC RACE Experiences Dr. Henry H. Ting, Mayo Clinic College of Medicine Dr. James G. Jollis,, Duke University Medical Center Mayo Clinic STEMI System for Transferred

More information

La fibrinolyse est- elle sous- u1lisée en France?

La fibrinolyse est- elle sous- u1lisée en France? La fibrinolyse est- elle sous- u1lisée en France? Nicolas DANCHIN, HEGP, Paris nicolasdanchin@yahoo.fr Research grants: Astra- Zeneca, Eli- Lilly, GSK, Merck, Novar1s, Pfizer, sanofi- aven1s, Servier,

More information

Myocardial Infarction In Dr.Yahya Kiwan

Myocardial Infarction In Dr.Yahya Kiwan Myocardial Infarction In 2007 Dr.Yahya Kiwan New Definition Of Acute Myocardial Infarction The term of myocardial infarction should be used when there is evidence of myocardial necrosis in a clinical setting

More information

Improving STEMI outcomes in Denmark. Michael Rahbek Schmidt, MD, PhD. Aarhus University Hospital Skejby Denmark

Improving STEMI outcomes in Denmark. Michael Rahbek Schmidt, MD, PhD. Aarhus University Hospital Skejby Denmark Improving STEMI outcomes in Denmark Michael Rahbek Schmidt, MD, PhD. Aarhus University Hospital Skejby Denmark Presenter Disclosure Information Study funded by Fondation Leducq Michael Rahbek Schmidt The

More information

Management of STEMI in era of Reperfusion. Eagles Peter Moyer, MD, MPH Medical Director Boston EMS, Fire and Police

Management of STEMI in era of Reperfusion. Eagles Peter Moyer, MD, MPH Medical Director Boston EMS, Fire and Police Management of STEMI in era of Reperfusion Eagles 2007 Peter Moyer, MD, MPH Medical Director Boston EMS, Fire and Police STEMI in US ST Segment Elevation Myocardial Infarction (STEMI) ~500 K per year Thrombolysis

More information

Thrombolysis in Cardiology to whom? Professor Steen D. Kristensen, MD, DMSc, FESC Department of Cardiology

Thrombolysis in Cardiology to whom? Professor Steen D. Kristensen, MD, DMSc, FESC Department of Cardiology Thrombolysis in Cardiology to whom? Professor Steen D. Kristensen, MD, DMSc, FESC Department of Cardiology UNIVERSITY OF AARHUS 1 COI Speakers fee: Aspen, AZ, Bayer, BMS/Pfizer Departmental research grant:

More information

Recognizing the High Risk NSTEMI Patient for Early Appropriate Therapy

Recognizing the High Risk NSTEMI Patient for Early Appropriate Therapy Recognizing the High Risk NSTEMI Patient for Early Appropriate Therapy Learning Objectives Learn to recognize the high risk patient Discuss effective management of a high risk NSTEMI patient Review CCS

More information

The Role of DHMC as an ST Elevation Myocardial Infarction Receiving Center in a Regional STEMI Care Network:

The Role of DHMC as an ST Elevation Myocardial Infarction Receiving Center in a Regional STEMI Care Network: The Role of DHMC as an ST Elevation Myocardial Infarction Receiving Center in a Regional STEMI Care Network: Nathaniel Niles, MD CREST Symposium November 7th, 28 STEMI = Acute Coronary Thrombosis STEMI

More information

Patient and System Time Delay

Patient and System Time Delay Quality Indicators in the Management of ST-elevation Myocardial Infarction Patient and System Time Delay Jacob Thorsted Sorensen, MD, PhD Department of Cardiology Aarhus University Hospital, Denmark Disclosures

More information

DECLARATION OF CONFLICT OF INTEREST

DECLARATION OF CONFLICT OF INTEREST DECLARATION OF CONFLICT OF INTEREST How to manage antiplatelet treatment in patients with diabetes in acute coronary syndrome Lars Wallentin Professor of Cardiology, Chief Researcher Cardiovascular Science

More information

I have no financial relationships to disclose

I have no financial relationships to disclose I have no financial relationships to disclose Networking decreases mortality Vasil Velchev,MD,PhD UH St. Anna Sofia time = myocardium = life Transfer for angioplasty vs. Immediate Thrombolysis (hospital

More information

PHARMACO-INVASIVE STRATEGY COMPARED WITH PPCI: DESIGN AND MAIN OUTCOMES OF THE STREAM TRIAL

PHARMACO-INVASIVE STRATEGY COMPARED WITH PPCI: DESIGN AND MAIN OUTCOMES OF THE STREAM TRIAL PHARMACO-INVASIVE STRATEGY COMPARED WITH PPCI: DESIGN AND MAIN OUTCOMES OF THE STREAM TRIAL Frans Van de Werf Leuven, Belgium Disclosures Study grant from Boehringer Ingelheim to perform the STREAM trial,

More information

Transfer in D2B. Scott D Friedman, MD FACC Medical Director, Cardiology Services Shore Health System of Maryland. The Problem

Transfer in D2B. Scott D Friedman, MD FACC Medical Director, Cardiology Services Shore Health System of Maryland. The Problem Transfer in D2B Scott D Friedman, MD FACC Medical Director, Cardiology Services Shore Health System of Maryland The Problem NRMI-5: North Carolina, July 2003- June 2004 NC Nation Guidelines N 2,738 79,927

More information

Update Guidelines in STEMI Management: Focus on Logistic and System Approach to Reperfusion Therapy

Update Guidelines in STEMI Management: Focus on Logistic and System Approach to Reperfusion Therapy March 14 th, 2018 The First Asia Forum in Emergency Medicine BNH Hospital, Bangkok, Thailand Update Guidelines in STEMI Management: Focus on Logistic and System Approach to Reperfusion Therapy Wacin Buddhari,

More information

9/24/2013. Thrombolytics in 2013: Never Say Never. September 19 th, 2013 Scott M Lilly, MD PhD. Clinical Case

9/24/2013. Thrombolytics in 2013: Never Say Never. September 19 th, 2013 Scott M Lilly, MD PhD. Clinical Case September 19 th, 2013 Scott M Lilly, MD PhD Thrombolytics in 2013: Never Say Never Clinical Case 2 1 Evolution of STEMI Therapy The importance of absolute rest in bed for several days is clear James B

More information

Treatment of ST-elevation myocardial infarction in China: Where are we?

Treatment of ST-elevation myocardial infarction in China: Where are we? Treatment of ST-elevation myocardial infarction in China: Where are we? Associate Professor, Yihong Sun, MD Peking University People s Hospital Beijing, China Disclosure conflict of Interest The Challenges

More information

How to manage ACS patients with Comorbidities? Patients with Renal Failure

How to manage ACS patients with Comorbidities? Patients with Renal Failure How to manage ACS patients with Comorbidities? Patients with Renal Failure François Schiele, MD, PhD Department of Cardiology, University Hospital Jean Minjoz, Besançon, France. Potential conflicts of

More information

Chest pain and troponins on the acute take. J N Townend Queen Elizabeth Hospital Birmingham

Chest pain and troponins on the acute take. J N Townend Queen Elizabeth Hospital Birmingham Chest pain and troponins on the acute take J N Townend Queen Elizabeth Hospital Birmingham 3 rd Universal Definition of Myocardial Infarction Type 1: Spontaneous MI related to atherosclerotic plaque rupture

More information

STEMI Management in Belgium

STEMI Management in Belgium STEMI Management in Belgium Results of Belgian STEMI registry Prof dr M Claeys University Hospital Antwerp Belgian Working Group of Acute cardiology Lethality of AMI 2-23: MKG data N= 44782 AMI in hospital

More information

STEMI Stents What next? Arshad Khan - HNE Clinical Research Fellow. Supervisors: Prof Boyle and Attia.

STEMI Stents What next? Arshad Khan - HNE Clinical Research Fellow. Supervisors: Prof Boyle and Attia. STEMI Stents What next? Arshad Khan - HNE Clinical Research Fellow. Supervisors: Prof Boyle and Attia. PART 1 Systems of care for STEMI. STEMI Management Coronary angiogram +/- stenting. Prehospital thrombolysis

More information

What about aborted infarction?

What about aborted infarction? Unanswered Qs in STEMI management Q3 What about aborted infarction? Is there consensus on the definition? Aborted infarction and TIME to treatment Aborted MI as an outcome measure? Conclusions By Dr Jason

More information

STEMI Linee guida ESC Maddalena Lettino, Italy

STEMI Linee guida ESC Maddalena Lettino, Italy STEMI Linee guida ESC 2017 Maddalena Lettino, Italy Disclosure Speaker fee: Aspen, Astra Zeneca, BMS, Boehringer, Eli Lilly, DaichiiSankio, Bayer, Pfizer, Sanofi Advisory board member: Astra Zeneca, Eli

More information

Meet the Guidelines Le principali novità che modificheranno la nostra pratica clinica: STEMI

Meet the Guidelines Le principali novità che modificheranno la nostra pratica clinica: STEMI Meet the Guidelines 2017. Le principali novità che modificheranno la nostra pratica clinica: STEMI Guido Parodi Cardiologia Interventistica AOU Sassari Scuola di Specializzazione in Malattie dell Apparato

More information

PPCI in STEMI. ESC at the 22nd Annual Conference of the Saudi Heart Association February 21th, 2011

PPCI in STEMI. ESC at the 22nd Annual Conference of the Saudi Heart Association February 21th, 2011 PPCI in STEMI Dr Hassan Mhish Interventional Cardiology Consultant Cardiology Fellowship Program Director Prince Salman Heart Center King Fahd Medical City Riyadh, KSA ESC at the 22nd Annual Conference

More information

Approach to Multi Vessel disease with STEMI

Approach to Multi Vessel disease with STEMI Approach to Multi Vessel disease with STEMI MANAGEMENT OF ST-ELEVATION MYOCARDIAL INFARCTION Dr. Thomas Alexander, M.D; D.M; F.A.C.C. Senior Consultant and Interventional Cardiologist Kovai Medical Centre

More information

GUIDELINE 14 ACUTE CORONARY SYNDROMES

GUIDELINE 14 ACUTE CORONARY SYNDROMES AUSTRALIAN RESUSCITATION COUNCIL GUIDELINE 14 ACUTE CORONARY SYNDROMES OVERVIEW AND SUMMARY As a part of the International Liaison Committee on Resuscitation (ILCOR) process that led to the International

More information

Disclosures. Speaker s bureau: Research grant: Advisory Board: Servier International, Bayer, Merck Serono, Novartis, Boehringer Ingelheim, Lupin

Disclosures. Speaker s bureau: Research grant: Advisory Board: Servier International, Bayer, Merck Serono, Novartis, Boehringer Ingelheim, Lupin Disclosures Speaker s bureau: Research grant: Advisory Board: Servier International, Bayer, Merck Serono, Novartis, Boehringer Ingelheim, Lupin Servier International, Boehringer Ingelheim Servier International,

More information

Ischemic and bleeding risk stratification in NSTE ACS. Andrzej Budaj Postgraduate Medical School Grochowski Hospital, Warsaw, Poland

Ischemic and bleeding risk stratification in NSTE ACS. Andrzej Budaj Postgraduate Medical School Grochowski Hospital, Warsaw, Poland Ischemic and bleeding risk stratification in NSTE ACS Andrzej Budaj Postgraduate Medical School Grochowski Hospital, Warsaw, Poland Disclosure Andrzej Budaj, MD, PhD, reports the following potential conflicts

More information

Facilitated Percutaneous Coronary Intervention in Acute Myocardial Infarction. Is it beneficial to patients?

Facilitated Percutaneous Coronary Intervention in Acute Myocardial Infarction. Is it beneficial to patients? Facilitated Percutaneous Coronary Intervention in Acute Myocardial Infarction Is it beneficial to patients? Seung-Jea Tahk, MD. PhD. Suwon, Korea Facilitated PCI.. background Degree of coronary flow at

More information

ACUTE CORONARY SYNDROME PCI IN THE ELDERLY

ACUTE CORONARY SYNDROME PCI IN THE ELDERLY ACUTE CORONARY SYNDROME PCI IN THE ELDERLY G.KARABELA MD.PhD ATHENS NAVAL HOSPITAL INTERVENTIONAL CARDIOLOGY DEPARTMENT NO CONFLICT OF INTEREST TO DECLAIRE Risk stratification in Αcute Coronary Syndrome.

More information

Acute Coronary Syndrome

Acute Coronary Syndrome Acute Coronary Syndrome Clinical Manifestation of CAD Silent Ischemia/asymptomatic Stable Angina Acute Coronary Syndrome (Non- STEMI/UA and STEMI) Arrhythmias Heart Failure Sudden Death Pain patterns with

More information

NEBRASKA STEMI CONFERENCE 2015 Dr. Doug Kosmicki. 2013, American Heart Association

NEBRASKA STEMI CONFERENCE 2015 Dr. Doug Kosmicki. 2013, American Heart Association NEBRASKA STEMI CONFERENCE 2015 Dr. Doug Kosmicki 2013, American Heart Association 1 Dr. Doug Kosmicki Reperfusion Strategies Disclosure Information Report any disclosure information of conflicts of interest.

More information

State of the art lecture: 21st Century Post resuscitation management

State of the art lecture: 21st Century Post resuscitation management State of the art lecture: 21st Century Post resuscitation management ACCA Masterclass 2017 Prof Alain CARIOU Intensive Care Unit - Cochin Hospital (APHP) Paris Descartes University INSERM U970 - France

More information

2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non ST-Elevation Myocardial Infarction

2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non ST-Elevation Myocardial Infarction 2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non ST-Elevation Myocardial Infarction Ramzi Khalil MD FACC Assistant Professor Allegheny Gen.Hospital AHN Speakers

More information

Facilitated Percutaneous Coronary Intervention in STEMI Patients: Does It Work in Asian Patients?

Facilitated Percutaneous Coronary Intervention in STEMI Patients: Does It Work in Asian Patients? Editorial Comment Acta Cardiol Sin 2014;30:292 297 Facilitated Percutaneous Coronary Intervention in STEMI Patients: Does It Work in Asian Patients? Wei-Chun Huang, 1,2,3 Cheng-Hung Chiang 1,2 and Chun-Peng

More information

STEMI Presentation and Case Discussion. Case #1

STEMI Presentation and Case Discussion. Case #1 STEMI Presentation and Case Discussion Scott M Lilly MD PhD, Interventional Cardiology The Ohio State University Contemporary Multidisciplinary Cardiovascular Conference Orlando, Florida September 17 th,

More information

A.K. Gitt, F. Towae, C. Juenger, A. Papp, R. Zahn, U. Zeymer, J. Senges For the STAR-Study-Group Herzzentrum Ludwigshafen, Germany

A.K. Gitt, F. Towae, C. Juenger, A. Papp, R. Zahn, U. Zeymer, J. Senges For the STAR-Study-Group Herzzentrum Ludwigshafen, Germany Impact of Interventional Versus Conservative Approach on 5-Year-Mortality of Patients With Stable Angina and Documented Coronary Artery Disease in Clinical Practice: Results of the STAR-Registry A.K. Gitt,

More information

The role of pre hospital thrombolysis. Aaron Frimerman Hillel Yaffe Medical Center Hadera Israel

The role of pre hospital thrombolysis. Aaron Frimerman Hillel Yaffe Medical Center Hadera Israel The role of pre hospital thrombolysis Aaron Frimerman Hillel Yaffe Medical Center Hadera Israel Is thrombolysis still valid? Disclosure I am an Interventional Cardiologist STEMI is mainly a thrombotic

More information

Clinical and Economic Value of Rivaroxaban in Coronary Artery Disease

Clinical and Economic Value of Rivaroxaban in Coronary Artery Disease CHRISTOPHER B. GRANGER, MD Professor of Medicine Division of Cardiology, Department of Medicine; Director, Cardiac Care Unit Duke University Medical Center, Durham, NC Clinical and Economic Value of Rivaroxaban

More information

SHOULD BETA BLOCKERS BE USED ROUTINELY IN POST MI PATIENTS WITH PRESERVED LV FUNCTION?

SHOULD BETA BLOCKERS BE USED ROUTINELY IN POST MI PATIENTS WITH PRESERVED LV FUNCTION? SHOULD BETA BLOCKERS BE USED ROUTINELY IN POST MI PATIENTS WITH PRESERVED LV FUNCTION? Doron Zahger, MD Department of Cardiology, Soroka University Medical Center, Faculty of Health Sciences, Ben Gurion

More information

Disclosures. Dr. Scirica has also served as a consultant for Lexicon, Arena, Gilead, and Eisai.

Disclosures. Dr. Scirica has also served as a consultant for Lexicon, Arena, Gilead, and Eisai. Disclosures Benjamin M. Scirica, MD, MPH, is employed by the TIMI Study Group, which has received research grants from Abbott, AstraZeneca, Amgen, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb,

More information

A Patient Unsuitable for VKA Treatment

A Patient Unsuitable for VKA Treatment Will Apixaban change practice in atrial fibrillation? A Patient Unsuitable for VKA Treatment Professor Yoseph Rozenman The E. Wolfson Medical Center Jerusalem June 2013 Disclosures I have the following

More information

Subsequent management and therapies

Subsequent management and therapies ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Subsequent management and therapies Marco Valgimigli, MD, PhD University of Ferrara ITALY

More information

Antithrombotic therapy in the ACS patient with atrial fibrillation

Antithrombotic therapy in the ACS patient with atrial fibrillation Antithrombotic therapy in the ACS patient with atrial fibrillation Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Emergency Medicine Wilhelminenhospital Vienna, Austria Great Minds,

More information

Decline in CV-Mortality

Decline in CV-Mortality Lipids id 2013 What s Changed? Christopher Granger, MD Disclosure Research contracts: AstraZeneca, GSK, Merck, Sanofi- Aventis, BMS, Pfizer, The Medicines Company, Medtronic Foundation, and Boehringer

More information

Management of ST-elevation myocardial infarction Update 2009 Late comers: which options?

Management of ST-elevation myocardial infarction Update 2009 Late comers: which options? European Society of Cardiology Annual Session 2009 Management of ST-elevation myocardial infarction Update 2009 Late comers: which options? Antonio Abbate, MD Assistant Professor of Medicine Virginia Commonwealth

More information

Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death!

Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death! Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death! Robert C. Welsh, MD, FRCPC Associate Professor of Medicine Director, Adult Cardiac Catheterization

More information

Thrombolysis, adjunctive pharmacology and interventions

Thrombolysis, adjunctive pharmacology and interventions ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation ESC Annual Congress Munich, 2012 Thrombolysis, adjunctive pharmacology and interventions

More information

Antithrombotic Therapy in ACS Pretreatment in STEMI. Christian W. Hamm Kerckhoff Heart & Thorax Center Bad Nauheim Germany

Antithrombotic Therapy in ACS Pretreatment in STEMI. Christian W. Hamm Kerckhoff Heart & Thorax Center Bad Nauheim Germany Antithrombotic Therapy in ACS Pretreatment in STEMI Christian W. Hamm Kerckhoff Heart & Thorax Center Bad Nauheim Germany Potential conflicts of interest Speaker s name: Christian W. Hamm I have the following

More information

What is new in the Treatment of STEMI? Malcolm R. Bell, MBBS Mayo Clinic Rochester, MN

What is new in the Treatment of STEMI? Malcolm R. Bell, MBBS Mayo Clinic Rochester, MN What is new in the Treatment of STEMI? Malcolm R. Bell, MBBS Mayo Clinic Rochester, MN October 2011 Part 2 Summary of newer antithrombotic and antiplatelet agents in STEMI Role of thrombectomy in PPCI

More information

Frans Van de Werf, MD, PhD Leuven, Belgium

Frans Van de Werf, MD, PhD Leuven, Belgium STEMI Cases and the ESC STEMI Guidelines Frans Van de Werf, MD, PhD Leuven, Belgium The Easy Case 2/21/2011 History and Risk Factors 50-year old male patient Past medical history: Teratoma right testis

More information

Quale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor

Quale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor Quale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor Leonardo Bolognese Cardiovascular Department, Arezzo, Italy Platelet Reactivity in Patients with STEMI Undergoing Primary PCI Campo G et

More information

Trial Update- TOTAL. Jonathan Byrne

Trial Update- TOTAL. Jonathan Byrne Trial Update- TOTAL Jonathan Byrne No conflicts of interest Background- rationale for thrombectomy Major Limitation of primary PCI: distal embolisation and reduced flow Stonel JACC 2002;39:591-7 Henriques

More information

Mode of admission and its effect on quality indicators in Belgian STEMI patients

Mode of admission and its effect on quality indicators in Belgian STEMI patients 2015 Mode of admission and its effect on quality indicators in Belgian STEMI patients Prof dr M Claeys National Coordinator STEMI registry 29-6-2015 Background The current guidelines for the management

More information

Cardiac arrest in patients with coronary artery disease. Claude LE FEUVRE Institut de Cardiologie Pitié-Salpêtrière

Cardiac arrest in patients with coronary artery disease. Claude LE FEUVRE Institut de Cardiologie Pitié-Salpêtrière Cardiac arrest in patients with coronary artery disease Claude LE FEUVRE Institut de Cardiologie Pitié-Salpêtrière Disclosure Statement of Financial Interest I currently have, or have had over the last

More information

Review and presentation of current literature Dr. Nainesh Patel, Lehigh Valley Health System, PA

Review and presentation of current literature Dr. Nainesh Patel, Lehigh Valley Health System, PA Why the Cath Lab for the Cardiac Arrest Patient? Dr. Michael Mooney Dr. Nainesh Patel Dr. John McPhereson Dr. Paul McMullan Dr. David Seder Review and presentation of current literature Dr. Nainesh Patel,

More information

Optimal antithrombotic therapy:

Optimal antithrombotic therapy: Optimal antithrombotic therapy: upstream and during primary PCI. Steen D Kristensen, MD, DMSc, FESC Professor and Consultant Interventional Cardiologist Aarhus University, Denmark UNIVERSITY OF AARHUS

More information

How to approach non-infarct related artery disease in patients with STEMI in a limited resource setting

How to approach non-infarct related artery disease in patients with STEMI in a limited resource setting How to approach non-infarct related artery disease in patients with STEMI in a limited resource setting Ahmed A A Suliman, MBBS, FACP, FESC Associate Professor, University of Khartoum Interventional Cardiologist,

More information

Original Investigation

Original Investigation Research Original Investigation Fibrinolysis Use Among Patients Requiring Interhospital Transfer for ST-Segment Elevation Myocardial Infarction Care A Report From the US National Cardiovascular Data Registry

More information

2010 ACLS Guidelines. Primary goals of therapy for patients

2010 ACLS Guidelines. Primary goals of therapy for patients 2010 ACLS Guidelines Part 10: Acute Coronary Syndrome Present : 內科 R1 鍾伯欣 Supervisor: F1 吳亮廷 991110 Primary goals of therapy for patients of ACS Reduce the amount of myocardial necrosis that occurs in

More information

ISCHEMIC HEART DISEASE

ISCHEMIC HEART DISEASE ESC CONGRESS HIGHLIGHTS ISCHEMIC HEART DISEASE Francesco Cosentino (Stockholm, S) Declaration of Interest Advisory Board/Speaker: AstraZeneca, Roche, Boehringer-Ingelheim, Bristol-Myers Squibb, Merck,

More information

NSTE ACS. Timing of intervention

NSTE ACS. Timing of intervention NSTE ACS Timing of intervention Timing of intervention in NSTE-ACS What do the guidelines tell us? Any need for immediate invasive approach? No mortality benefit with an early invasive approach? Putting

More information

FFR-guided Complete vs. Culprit Only Revascularization in AMI Patients Ki Hong Choi, MD On Behalf of FRAME-AMI Investigators

FFR-guided Complete vs. Culprit Only Revascularization in AMI Patients Ki Hong Choi, MD On Behalf of FRAME-AMI Investigators FFR-guided Complete vs. Culprit Only Revascularization in AMI Patients Ki Hong Choi, MD On Behalf of FRAME-AMI Investigators Heart Vascular Stroke Institute, Samsung Medical Center, Seoul, Republic of

More information

Post resuscitation care and role of urgent angiography after cardiac arrest. Georg Fuernau Luebeck

Post resuscitation care and role of urgent angiography after cardiac arrest. Georg Fuernau Luebeck Post resuscitation care and role of urgent angiography after cardiac arrest Georg Fuernau Luebeck The journey CPR and guidelines European Resuscitation Council American Heart Association International

More information

Industry Relationships and Institutional Affiliations

Industry Relationships and Institutional Affiliations Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated daily statin: results from the ODYSSEY COMBO II study Christopher

More information

Timing of angiography for high- risk ACS

Timing of angiography for high- risk ACS Timing of angiography for high- risk ACS Christian Spaulding, MD, PhD, FESC, FACC Cardiology Department Cochin Hospital, Inserm U 970 Paris Descartes University Paris, France A very old story. The Interventional

More information

Controversies on Primary angioplasty in STEMI

Controversies on Primary angioplasty in STEMI Controversies on Primary angioplasty in STEMI 원주의대이승환 Case ( 51/M) CC C.C: ongoing squeezing chest pain D : for 2 hours Risk factors Current smoker ( 40 PYs) Hypercholesterolemia (+) Case ( 51/M) Physical

More information

French Registry on Acute ST-elevation and non ST-elevation Myocardial Infarction FAST-MI 2010

French Registry on Acute ST-elevation and non ST-elevation Myocardial Infarction FAST-MI 2010 French Registry on Acute ST-elevation and non ST-elevation Myocardial Infarction 2010. FAST-MI 2010 Registry Michel Hanssen, 1 Yves Cottin, 2 Khalife Khalife, 3 Laure Hammer, 4 Patrick Goldstein, 5 Etienne

More information

Acute Coronary Syndrome (ACS) is the consequence of

Acute Coronary Syndrome (ACS) is the consequence of Clinical Practice Pharmaco-invasive Therapy for STEMI; The Most Suitable STEMI Reperfusion Therapy for Transferred Patients in Thailand Pradub Sukhum, MD. 1 1 Division of Cardiovascular Medicine, Bangkok

More information

Management of Cardiogenic shock. Prof. Christian JM Vrints

Management of Cardiogenic shock. Prof. Christian JM Vrints Management of Cardiogenic shock Prof. Christian JM Vrints none conflicts Management of Cardiogenic Shock Incidence and trends Importance of early revascularization Multivessel disease Left main disease

More information

DISCUSSION QUESTION - 1

DISCUSSION QUESTION - 1 CASE PRESENTATION 87 year old male No past history of diabetes, HTN, dyslipidemia or smoking Very active Medications: omeprazole for heart burn Admitted because of increasing retrosternal chest pressure

More information

Culprit PCI vs MultiVessel PCI for Acute Myocardial Infarction

Culprit PCI vs MultiVessel PCI for Acute Myocardial Infarction Culprit PCI vs MultiVessel PCI for Acute Myocardial Infarction Dipti Itchhaporia, MD, FACC, FESC Trustee, American College of Cardiology Director of Disease Management, Hoag Hospital Robert and Georgia

More information

PCI Strategies After Fibrinolytic Therapy

PCI Strategies After Fibrinolytic Therapy PCI Strategies After Fibrinolytic Therapy How to choose the appropriate reperfusion strategy. BY MICHEL R. LE MAY, MD Survival in patients presenting with ST-segment elevation myocardial infarction (STEMI)

More information

Is There a Role For Pharmacokinetic/ Pharmacodynamics Guided Dosing For Novel Anticoagulants? Christopher Granger

Is There a Role For Pharmacokinetic/ Pharmacodynamics Guided Dosing For Novel Anticoagulants? Christopher Granger Is There a Role For Pharmacokinetic/ Pharmacodynamics Guided Dosing For Novel Anticoagulants? Christopher Granger 1 Disclosures Research contracts: Armetheon, AstraZeneca, Bayer, Boehringer Ingelheim,

More information

Andreas Baumbach Bristol Heart Institute Bristol Royal Infirmary. London 27/1/2005

Andreas Baumbach Bristol Heart Institute Bristol Royal Infirmary. London 27/1/2005 Andreas Baumbach Bristol Heart Institute Bristol Royal Infirmary AB London 27/1/2005 Revascularisation in ACS ICTUS MERLIN REACT 4mins 4mins 4mins AB Tony s Comments 15mins ICTUS Comparison of an early

More information

A Patient with Chest Pain and Atrial Fibrillation

A Patient with Chest Pain and Atrial Fibrillation A Patient with Chest Pain and Atrial Fibrillation Kurt Huber, Vienna, Austria Declaration of Interest Lecturing & Consulting Activities: AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi

More information